selegiline has been researched along with Cognition Disorders in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (37.50) | 18.2507 |
| 2000's | 13 (40.63) | 29.6817 |
| 2010's | 7 (21.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Auinger, P; Christine, CW; Green, R; Joslin, A; Yelpaala, Y | 1 |
| da Cunha, C; Ferreira, AP; Ferreira, J; Gomes, GM; Mello, CF; Pazini, AM; Pinheiro, F; Rubin, MA; Villarinho, JG | 1 |
| Alamri, Y; Anderson, TJ; Dalrymple-Alford, JC; Espiner, EA; Prickett, TC | 1 |
| Auinger, P; Cain, KC; Cholerton, B; Ginghina, C; Liu, C; Shi, M; Stewart, T; Zhang, J | 1 |
| Auinger, P; Cain, KC; Cholerton, B; Ginghina, C; Liu, C; Shi, M; Zhang, J | 1 |
| Campbell, S; Kozan, B; Trettien, A | 1 |
| Anderson, SW; Auinger, P; Chou, KL; Como, PG; Growdon, JC; Litvan, I; Marder, KS; McDermott, MP; Uc, EY | 1 |
| Anderson, C; Clifford, DB; Ernst, T; Marra, CM; Nath, A; Navia, BA; Sacktor, N; Schifitto, G; Yiannoutsos, CT | 1 |
| Holford, NH; Nutt, JG; Vu, TC | 2 |
| Sano, M | 1 |
| Hatakeyama, Y; Nakano, N; Yoshida, T | 1 |
| Kang, SY; Lee, MH; Lee, SK; Sohn, YH | 1 |
| Landsberg, G | 1 |
| Tariot, PN | 1 |
| Ames, D; Ritchie, C | 1 |
| Lang, AE; Marras, C; McDermott, MP; Naglie, G; Rochon, PA; Tanner, CM | 1 |
| Berry, MD; Juorio, AV; Paterson, IA | 1 |
| Brady, J; Carter, J; Como, P; Growdon, J; Huber, S; Kanigan, B; Kieburtz, K; Landow, E; McDermott, M; Rudolph, A | 1 |
| Bruyette, DS; Cotman, CW; Cummings, BJ; DePaoli, A; Head, E; Milgram, NW; Ruehl, WW | 1 |
| Brownlee, HJ; Stacy, M | 1 |
| Bruyette, DS; Cummings, BJ; Hart, B; Head, E; Neilson, J; Ruehl, WW | 1 |
| O'Toole, D | 1 |
| Filip, V; Kolibás, E | 1 |
| Di Rocco, A | 1 |
| Bianchin, M; Quevedo, J; Roesler, R; Walz, R | 1 |
| Kieburtz, K; Marder, K; McArthur, JC; McDermott, MP; Sacktor, N; Schifitto, G | 1 |
| Grundman, M | 1 |
| Hamm, RJ; Phillips, LL; Povlishock, JT; Reeves, TM; Zhu, J | 1 |
| Davis, CM; Fuselier, CC; Goad, DL; Liem, P; McCormack, JR; Olsen, KM | 1 |
| Curry, SH; Eatough, VM; Frankel, JP; Kempster, PA; Lees, AJ; Rogers, D; Stern, GM | 1 |
8 review(s) available for selegiline and Cognition Disorders
| Article | Year |
|---|---|
Noncholinergic treatment options for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Animals; Anticholesteremic Agents; Antioxidants; Behavioral Symptoms; Clinical Trials as Topic; Cognition Disorders; Estrogens; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Middle Aged; Patient Selection; Research Design; Selegiline; Vitamin E | 2003 |
[Mild cognitive impairment].
Topics: Aging; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Diagnosis, Differential; Disease Progression; Humans; Psychiatric Status Rating Scales; Selegiline; Severity of Illness Index; Vitamin E | 2003 |
Therapeutic agents for the treatment of cognitive dysfunction syndrome in senior dogs.
Topics: Aging; Animals; Behavior, Animal; Cognition Disorders; Complementary Therapies; Diet Therapy; Dogs; Environment; Humans; Neuroprotective Agents; Neuropsychological Tests; Selegiline | 2005 |
Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Humans; Memantine; Neuroprotective Agents; Nursing Homes; Patient Transfer; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate; Selegiline; Severity of Illness Index; Treatment Outcome; Vitamin E | 2006 |
Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders.
Topics: Aging; Alzheimer Disease; Animals; Cognition Disorders; Depressive Disorder; Humans; Longevity; Mental Disorders; Monoamine Oxidase Inhibitors; Nervous System Diseases; Parkinson Disease; Schizophrenia; Selegiline | 1994 |
Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: clinical presentation, cognitive testing, pathology and response to 1-deprenyl therapy.
Topics: Aging; Alzheimer Disease; Animals; Cognition Disorders; Dementia; Disease Models, Animal; Dogs; Humans; Selegiline | 1995 |
Treatment options for early Parkinson's disease.
Topics: Algorithms; Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Cognition Disorders; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline | 1996 |
Vitamin E and Alzheimer disease: the basis for additional clinical trials.
Topics: Alzheimer Disease; Animals; Antioxidants; Brain; Clinical Trials as Topic; Cognition Disorders; Humans; Lipid Peroxidation; Monoamine Oxidase Inhibitors; Oxidative Stress; Selegiline; Vitamin E | 2000 |
13 trial(s) available for selegiline and Cognition Disorders
| Article | Year |
|---|---|
Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease.
Topics: alpha-Tocopherol; Antioxidants; Antiparkinson Agents; Cognition Disorders; Double-Blind Method; Female; Follow-Up Studies; Homocysteine; Humans; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Predictive Value of Tests; Selegiline; Treatment Outcome; Vitamin B 12 | 2018 |
Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.
Topics: Adult; Aged; Aged, 80 and over; alpha-Synuclein; alpha-Tocopherol; Antiparkinson Agents; Cognition Disorders; Cohort Studies; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Selegiline | 2014 |
CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.
Topics: Adult; Aged; Amyloid beta-Peptides; Antioxidants; Apolipoproteins E; Cognition Disorders; Cohort Studies; Cross-Sectional Studies; Female; Humans; Linear Models; Male; Middle Aged; Monoamine Oxidase Inhibitors; Neuropsychological Tests; Parkinson Disease; Peptide Fragments; Predictive Value of Tests; Selegiline; Severity of Illness Index; tau Proteins; Time Factors; Vitamin E | 2015 |
A noncomparative open-label study evaluating the effect of selegiline hydrochloride in a clinical setting.
Topics: Aging; Animals; Cognition Disorders; Dog Diseases; Dogs; Female; Male; Neuroprotective Agents; Selegiline | 2001 |
Selegiline and oxidative stress in HIV-associated cognitive impairment.
Topics: Adult; AIDS Dementia Complex; Biomarkers, Pharmacological; Cognition Disorders; Female; HIV Infections; Humans; Male; Middle Aged; Oxidative Stress; Selegiline | 2009 |
The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group.
Topics: Aged; Cognition Disorders; Female; Humans; Male; Middle Aged; Parkinson Disease; Selegiline; Vitamin E | 1994 |
A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antioxidants; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Placebos; Selegiline; Thioctic Acid; Treatment Outcome | 1998 |
Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Chi-Square Distribution; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Memory Disorders; Middle Aged; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Neuropsychological Tests; Prospective Studies; Selegiline | 1999 |
A randomized, double-blind, placebo-controlled trial of deprenyl and thiotic acid in HIV-associated cognitive impairment.
Topics: Antioxidants; Cognition Disorders; Double-Blind Method; Humans; Monoamine Oxidase Inhibitors; Selegiline; Thioctic Acid | 1999 |
A randomized, double-blind, placebo-controlled trial of deprenyl and thiotic acid in HIV-associated cognitive impairment.
Topics: Antioxidants; Cognition Disorders; Double-Blind Method; Humans; Monoamine Oxidase Inhibitors; Selegiline; Thioctic Acid | 1999 |
Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study.
Topics: Administration, Cutaneous; Adult; Cognition Disorders; Female; HIV Seropositivity; Humans; Male; Mental Recall; Middle Aged; Monoamine Oxidase Inhibitors; Motor Activity; Pilot Projects; Placebos; Psychomotor Performance; Selegiline; Verbal Learning | 2000 |
The use of selegiline in Alzheimer's patients with behavior problems.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Ambulatory Care; Cognition Disorders; Female; Home Nursing; Humans; Male; Mental Disorders; Middle Aged; Psychiatric Status Rating Scales; Selegiline; Single-Blind Method | 1991 |
Effects of L-deprenyl on parkinsonian bradyphrenia.
Topics: Adult; Attention; Cognition Disorders; Dementia; Double-Blind Method; Humans; Microcomputers; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Reaction Time; Selegiline | 1990 |
11 other study(ies) available for selegiline and Cognition Disorders
| Article | Year |
|---|---|
Selegiline reverses aβ₂₅₋₃₅-induced cognitive deficit in male mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cerebral Cortex; Cognition Disorders; Disease Models, Animal; Hippocampus; Male; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Selegiline | 2013 |
C-type natriuretic peptide in Parkinson's disease: reduced secretion and response to deprenyl.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cognition Disorders; Female; Humans; Male; Middle Aged; Natriuretic Peptide, C-Type; Parkinson Disease; Retrospective Studies; Selegiline; Severity of Illness Index; Time Factors | 2014 |
Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Antiparkinson Agents; Clinical Trials as Topic; Cognition Disorders; Female; Gastrointestinal Tract; Humans; Incidence; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Risk Assessment; Risk Factors; Selection Bias; Selegiline; Tocopherols; United States; Urogenital System | 2009 |
Progression of motor and nonmotor features of Parkinson's disease and their response to treatment.
Topics: Antiparkinson Agents; Cognition Disorders; Depression; Disability Evaluation; Disease Progression; Drug Substitution; Drug Therapy, Combination; Gait Disorders, Neurologic; Humans; Hypokinesia; Linear Models; Motor Activity; Nonlinear Dynamics; Parkinson Disease; Patient Dropouts; Postural Balance; Predictive Value of Tests; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Selegiline; Sensation Disorders; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Tocopherols; Treatment Outcome; Tremor | 2012 |
Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Chi-Square Distribution; Cognition; Cognition Disorders; Depression; Disability Evaluation; Disease Progression; Humans; Kaplan-Meier Estimate; Middle Aged; Parkinson Disease; Patient Dropouts; Predictive Value of Tests; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Selegiline; Severity of Illness Index; Time Factors; Tocopherols; Treatment Outcome | 2012 |
Levodopa-responsive parkinsonism in hereditary spastic paraplegia with thin corpus callosum.
Topics: Adolescent; Antiparkinson Agents; Benztropine; Cognition Disorders; Corpus Callosum; Electroencephalography; Female; Gait Disorders, Neurologic; Humans; Levodopa; Magnetic Resonance Imaging; Male; Muscle Weakness; Neuropsychological Tests; Parkinson Disease; Selegiline; Spastic Paraplegia, Hereditary; Tremor | 2004 |
Antioxidants and Alzheimer's disease: time to stop feeding vitamin E to dementia patients?
Topics: Aging; Alzheimer Disease; Antioxidants; Cognition Disorders; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidative Stress; Selegiline; Vitamin E | 2007 |
Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial.
Topics: Activities of Daily Living; Aged; Canada; Cognition Disorders; Cohort Studies; Depressive Disorder; Disease Progression; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Psychological Tests; Quality of Life; Randomized Controlled Trials as Topic; Retrospective Studies; Selegiline; Tocopherols; United States | 2008 |
Therapeutic actions of L-deprenyl in dogs: a model of human brain aging.
Topics: Aging; Animals; Brain; Cognition Disorders; Dementia; Dogs; Humans; Models, Biological; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Selegiline | 1998 |
Debate regarding news story on cognitive dysfunction in dogs and cats.
Topics: Alzheimer Disease; Animals; Cat Diseases; Cats; Cognition Disorders; Dog Diseases; Dogs; Humans; Neuroprotective Agents; Selegiline | 1998 |
Postinjury administration of L-deprenyl improves cognitive function and enhances neuroplasticity after traumatic brain injury.
Topics: Acetylcholinesterase; Animals; Axons; Brain Injuries; Cognition; Cognition Disorders; Disease Models, Animal; Dopamine beta-Hydroxylase; Entorhinal Cortex; Hippocampus; Male; Maze Learning; Motor Activity; Neural Pathways; Neuronal Plasticity; Rats; Rats, Sprague-Dawley; Recovery of Function; Selegiline; Time Factors | 2000 |